<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>367</serviceExecutionTime><Drug id="8244"><DrugName>linazolast</DrugName><DrugSynonyms><Name><Value>TMK-688</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>YM-257</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>TMK-777</Value><Types><Type>Research Code</Type><Type>Metabolite</Type></Types></Name><Name><Value>linazolast</Value></Name><Name><Value>110501-66-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20341">Terumo Corp</CompanyOriginator><CompaniesSecondary><Company id="20341">Terumo Corp</Company><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="8244" type="Drug"><TargetEntity id="134775" type="siDrug">Linetastine</TargetEntity></SourceEntity><SourceEntity id="20341" type="Company"><TargetEntity id="4295878607" type="organizationId">Terumo Corp</TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"></TargetEntity><TargetEntity id="D007249" type="MeSH"></TargetEntity><TargetEntity id="-308860612" type="omicsDisease"></TargetEntity><TargetEntity id="1181" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"></TargetEntity><TargetEntity id="493" type="ICD9"></TargetEntity><TargetEntity id="10003553" type="MEDDRA"></TargetEntity><TargetEntity id="D001249" type="MeSH"></TargetEntity><TargetEntity id="-1473716268" type="omicsDisease"></TargetEntity><TargetEntity id="270" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="477" type="ciIndication"><TargetEntity id="10039083" type="MEDDRA"></TargetEntity><TargetEntity id="D012220" type="MeSH"></TargetEntity><TargetEntity id="-535061555" type="omicsDisease"></TargetEntity><TargetEntity id="297" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="247" type="Action"><TargetEntity id="1296" type="Mechanism">5-Lipoxygenase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00032" type="ciTarget"><TargetEntity id="7159459062403" type="siTarget">Arachidonate 5-lipoxygenase</TargetEntity><TargetEntity id="-1163238542" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="188">Inflammatory disease</Indication><Indication id="31">Asthma</Indication><Indication id="477">Rhinitis</Indication></IndicationsSecondary><ActionsPrimary><Action id="247">5-Lipoxygenase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="1263">Immuno-oncology</Technology></Technologies><LastModificationDate>2017-11-28T15:40:13.000Z</LastModificationDate><ChangeDateLast>2017-11-28T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="8244"&gt;Linazolast&lt;/ulink&gt; is a 5-lipoxygenase inhibitor and was in phase III clinical trials by Terumo as a treatment for asthma. Data from this phase III study did not show an effect compared to the control drug and Terumo abandoned development for this indication in August 1996 [&lt;ulink linkType="reference" linkID="218852"&gt;218852&lt;/ulink&gt;]. It remained in phase II trials for allergic rhinitis [&lt;ulink linkType="reference" linkID="161054"&gt;161054&lt;/ulink&gt;] but subsequently all development of this product was abandoned by Terumo [&lt;ulink linkType="reference" linkID="234198"&gt;234198&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A solid formulation for oral administration of this product is claimed in EP-00537070.&lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="8244"&gt;Linazolast&lt;/ulink&gt; inhibits dimethylbenzanthracene induction of skin tumors and carcinogenesis caused by benzo[a]pyrene. Its mechanism involves the prevention of metabolic activation of these agents [&lt;ulink linkType="reference" linkID="175672"&gt;175672&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>1997-02-17T00:00:00.000Z</StatusDate><Source id="234198" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="477">Rhinitis</Indication><StatusDate>1997-02-17T00:00:00.000Z</StatusDate><Source id="234198" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20341">Terumo Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="477">Rhinitis</Indication><StatusDate>1997-02-17T00:00:00.000Z</StatusDate><Source id="234198" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="188">Inflammatory disease</Indication><StatusDate>1997-02-17T00:00:00.000Z</StatusDate><Source id="234198" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20341">Terumo Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="31">Asthma</Indication><StatusDate>1996-09-10T00:00:00.000Z</StatusDate><Source id="218852" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><Source id="173369" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="477">Rhinitis</Indication><Source id="173369" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20967">Yamanouchi Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><Source id="173369" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20341">Terumo Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="477">Rhinitis</Indication><Source id="173369" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20341">Terumo Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="31">Asthma</Indication><Source id="173369" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00032"><Name>5-Lipoxygenase</Name><SwissprotNumbers><Swissprot>P09917</Swissprot><Swissprot>P12527</Swissprot><Swissprot>P48999</Swissprot><Swissprot>P51399</Swissprot><Swissprot>Q7XV13</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1013295">Astellas Pharma Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20341">Terumo Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCOC(=O)Oc1ccc(cc1OC)/C=C/C=C/C(=O)NCCN2CCC(CC2)OC(c3ccccc3)c4ccccc4</Smiles></StructureSmiles><Deals><Deal id="121059" title="Yamanouchi to codevelop Terumo's linazolast in Japan"/></Deals><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>